Healthcare Services

Global Neuroendocrine Tumor Treatment Market Forecast 2026–2035: Long-Term Growth Insights

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neuroendocrine tumor treatment market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Neuroendocrine Tumor Treatment Market from 2026 to 2030?

The neuroendocrine tumor treatment market size has experienced significant expansion recently. Forecasts suggest it will rise from $2.39 billion in 2025 to $2.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.5%. This past growth can be attributed to several factors, including the early use of somatostatin analogs, an increase in neuroendocrine tumor cases, the initial introduction of targeted therapies, advancements in diagnostic imaging, and greater awareness of rare cancer types.

The neuroendocrine tumor treatment market is projected for swift expansion in the upcoming years. This market is anticipated to reach $3.98 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. Factors driving this growth over the forecast period include increased investment in PRRT innovations, wider acceptance of personalized oncology treatment, the expansion of immunotherapy in NET treatment, a growing number of available oncology care centers, and the creation of novel combination chemotherapy regimens. Key trends anticipated during this period encompass the increased application of somatostatin analogs to manage tumor growth, the rising uptake of targeted therapy options, higher usage of chemotherapy in advanced NET cases, the broadening scope of peptide receptor radionuclide therapy (PRRT), and a growing need for multidisciplinary oncology care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12248&type=smp

What Drivers Are Affecting Demand In The Neuroendocrine Tumor Treatment Market?

The increasing occurrence of neuroendocrine tumors is anticipated to significantly boost the expansion of the neuroendocrine tumor treatment market in the foreseeable future. Neuroendocrine tumors, often referred to as NETs, are uncommon growths that develop from neuroendocrine cells. Treating neuroendocrine tumors is a crucial process, aiming to manage symptoms, inhibit tumor progression, and eliminate tumor cells through methods like radiation therapy. For example, in 2024, data from NeuroEndocrine Cancer Australia (NECA), an Australian advocacy, education, and research group, projected that approximately 21.1 per 100,000 people would receive a neuroendocrine tumor (NETs) diagnosis, amounting to roughly 5,755 new diagnoses. The 39-year prevalence was also estimated at 29,351 individuals living with NETs. Consequently, the rising incidence of neuroendocrine tumors is a key factor driving the growth of the neuroendocrine tumor treatment market.

Which Segments Are Gaining Traction In The Neuroendocrine Tumor Treatment Market?

The neuroendocrine tumor treatment market covered in this report is segmented –

1) By Product: Somatostatin Analogs (SSAs), Targeted Therapy, Chemotherapy, Other Products

2) By Indication: Lungs, Pancreas, Gastrointestinal, Other Indications

3) By End-User: Hospitals, Oncology Centers, Other End-Users

Subsegments:

1) By Somatostatin Analogs (SSAs): Octreotide, Lanreotide

2) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Peptide Receptor Radionuclide Therapy (PRRT)

3) By Chemotherapy: Traditional Chemotherapy Agents, Combination Chemotherapy Regimens

4) By Other Products: Immunotherapy, Supportive Care Medications

Which Market Trends Are Opening Growth Opportunities In The Neuroendocrine Tumor Treatment Market?

Leading companies in the neuroendocrine tumor treatment market are concentrating on advancing therapeutic solutions, such as radioligand therapies, to improve clinical results and offer more treatment choices for patients with GEP-NETs. Radioligand therapy is a focused treatment method that delivers radioactive isotopes directly to tumor cells that express specific receptors, allowing for precise tumor cell elimination while minimizing harm to surrounding healthy tissues. For example, in April 2024, Novartis, a Switzerland-based healthcare company, announced that the U.S. Food and Drug Administration (FDA) had approved Lutathera. This product is the first radioligand therapy specifically approved for pediatric patients aged 12 years and older suffering from somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This approval expands the availability of targeted radiopharmaceutical treatment for younger NET patients and underscores the increasing importance of radioligand therapies in enhancing treatment effectiveness, clinical decision-making, and overall patient care.

Who Are The Major Companies Operating In The Neuroendocrine Tumor Treatment Market?

Major companies operating in the neuroendocrine tumor treatment market are Pfizer Inc, F Hoffmann-La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical, Ipsen Pharma SAS, Jiangsu Hengrui Medicine, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, Ascentage Pharma, Debiopharm, Boehringer Ingelheim International GmbH, Hutchison MediPharma Ltd, Exelixis Inc, EpicentRx Inc, Tarveda Therapeutics, Teclison Ltd, Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Neuroendocrine Tumor Treatment Market?

North America was the largest region in the neuroendocrine tumor treatment market in 2025. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neuroendocrine Tumor Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12248&type=smp

Browse Through More Reports Similar to the Global Neuroendocrine Tumor Treatment Market 2026, By The Business Research Company

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Glioma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795